ClinicalTrials.gg
Drug

Bimekizumab clinical trials

Also written UCB4940 and Bimzelx.

studies test it
51
open now
9
in phase 3
24
first study started
2012

How each study uses bimekizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the bimekizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
17 Oct 2023 · BIMZELX · BLA 761151 (FDA, Drugs@FDA)
European Union
20 Aug 2021 · Bimzelx · EMEA/H/C/005316 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Bimekizumab
49
BKZ
18

Brand

Bimzelx
5

Development codes

UCB4940
33

Studies by the year they started

51 studies that test it; most in 2019 (7)

Studies that test bimekizumab, by start year
YearStudies
20121
20141
20166
20176
20185
20197
20205
20213
20221
20232
20244
20256
20264

By phase

A phase 1/2 study counts in both.

Phase 1
8
Phase 2
14
Phase 3
24
Phase 4
5

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 42 · Other 9

UCB Biopharma SRL (34) · UCB Biopharma S.P.R.L. (5) · UCB Celltech (3) · Icahn School of Medicine at Mount Sinai (1) · Radboud University Medical Center (1) · University Hospital, Rouen (1) · Mayo Clinic (1) · Oregon Health and Science University (1)

Often tested with

Tested in the same studies.

Secukinumab (3) · Ixekizumab (3) · Guselkumab (3) · Risankizumab (3) · Certolizumab Pegol (3) · Tildrakizumab (2) · Tacrolimus (2) · Adalimumab (2)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 3, 2 in phase 3

Studies that test bimekizumab, phase 3 first.

Studies

Open first, then newest update. How each study uses bimekizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 51

See all 51 studies that test bimekizumab →

Given beside what is tested · 3 — bimekizumab is usual care or a partner of the new treatment

Codes

What other systems call bimekizumab · ClinicalTrials.gg INT000884

  • MeSH (NLM) C000625981bimekizumabConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 09495UIM6VBIMEKIZUMABConfirmed FDA, NLM, Wikidata
  • Wikidata Q60785566bimekizumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C171829BimekizumabOne source FDA
  • DrugBank DB12917One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.